Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medicinova (MNOV) EPS (Weighted Average and Diluted) (2021 - 2025)

Medicinova (MNOV) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.07 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) changed N/A to -$0.07 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.26 through Dec 2025, changed N/A year-over-year, with the annual reading at -$0.24 for FY2025, 4.35% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.07 at Medicinova, down from -$0.06 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was -$0.01 in Q3 2023, with the low at -$0.09 in Q2 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.06, with a median of -$0.06 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) soared 85.71% in 2023, then plummeted 500.0% in 2024.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.04 in 2021, then plummeted by 75.0% to -$0.07 in 2022, then skyrocketed by 42.86% to -$0.04 in 2023, then crashed by 50.0% to -$0.06 in 2024, then fell by 16.67% to -$0.07 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.07, -$0.06, and -$0.07 for Q4 2025, Q3 2025, and Q2 2025 respectively.